Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Theodore R Brown"'
Autor:
Herb Karpatkin, Eric Garmon, Ulrik Dalgas, Barbara Giesser, June Halper, Theodore R Brown, Robert W. Motl, Lara A. Pilutti, Kathleen Costello, Kathleen M. Zackowski, Jennifer Keller, Amanda Rohrig, Alexander V. Ng, Paul Van Asch, Susan Coote, Rosalind Kalb
Publikováno v:
Kalb, R, Brown, T R, Coote, S, Costello, K, Dalgas, U, Garmon, E, Giesser, B, Halper, J, Karpatkin, H, Keller, J, Ng, A V, Pilutti, L A, Rohrig, A, Van Asch, P, Zackowski, K & Motl, R W 2020, ' Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course ', Multiple Sclerosis Journal, vol. 26, no. 12, pp. 1459-1469 . https://doi.org/10.1177/1352458520915629
Multiple Sclerosis (Houndmills, Basingstoke, England)
Multiple Sclerosis (Houndmills, Basingstoke, England)
Objectives: To provide clinicians who treat multiple sclerosis (MS) patients with evidence-based or expert opinion–based recommendations for promoting exercise and lifestyle physical activity across disability levels. Methods: The National MS Socie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fa9f05502dd08da5a772eecdfe45eaf
https://pure.au.dk/ws/files/220255409/1352458520915629.pdf
https://pure.au.dk/ws/files/220255409/1352458520915629.pdf
Autor:
James D. Bowen, Kyle Smoot, Annette Wundes, Pavle Repovic, Justine Brink, Elisabeth B. Lucassen, Theodore R. Brown
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is marked by a wide range and severity of symptoms. Most patients have mild to moderate symptoms, whereas 10%–15% require hospitalizati
Autor:
Theodore R Brown, Virginia I. Simnad
Publikováno v:
Int J MS Care
Background: Injection pain and fear of pain are common with subcutaneous medications for treating multiple sclerosis (MS). Synera is a peel-and-stick topical adhesive (S-TA) with a novel heating component to enhance the delivery of an anesthetic mixt
Autor:
Theodore R Brown, Virginia I. Simnad
Publikováno v:
International Journal of MS Care. 18:170-176
Background: Dalfampridine extended release (D-ER) is indicated to improve walking in people with multiple sclerosis (MS) as demonstrated by an increase in walking speed. This study assessed the effects of D-ER on accelerometer-based measures in peopl
Autor:
Albert C. Lo, Christina Hughes, Lily Jung Henson, Jodie K. Haselkorn, George H. Kraft, Theodore R. Brown, Christopher T. Bever, Gary S. Gronseth, Pushpa Narayanaswami, Alexander Rae-Grant, Melissa J. Armstrong
Publikováno v:
Neurology. Clinical practice. 7(3)
We thank Sutliff et al.1 for their commentary on our systematic review (SR), “Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis.”2 We would like to make several points in response. (A more extensive response is avai
Autor:
Jodie K. Haselkorn, George H. Kraft, Gary S. Gronseth, Albert C. Lo, Lily Jung Henson, Thomas S.D. Getchius, Pushpa Narayanaswami, Melissa J. Armstrong, Christina Hughes, Alex Rae-Grant, Christopher T. Bever, Theodore R. Brown
Publikováno v:
Neurology. 85:1896-1903
Objective: To systematically review the evidence regarding rehabilitation treatments in multiple sclerosis (MS). Methods: We systematically searched the literature (1970–2013) and classified articles using 2004 American Academy of Neurology criteri
Autor:
Theodore R Brown, April Slee
Publikováno v:
International Journal of MS Care. 17:83-89
Background: Pain is common in multiple sclerosis (MS). Duloxetine has a potential therapeutic role in treating MS-related pain. Methods: Thirty-eight MS patients were randomized 1:1 to receive duloxetine (n = 18) or matched placebo (n = 20). The dosi
Autor:
Randall T Schapiro, Extension Study Investigators, Francois Bethoux, Andrew D. Goodman, Theodore R Brown, Andrew R. Blight, Ronald A. Cohen, Lawrence Marinucci, Herbert R. Henney
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release fampridine in Europe; fampridine modified or sustained release elsewhere) improved walking
Publikováno v:
Journal of Medical Economics. 13:626-632
Multiple sclerosis (MS) is associated with a substantial economic burden resulting from direct medical costs associated with health and disability-related resource utilization and indirect costs relating to reduced productivity. However, reduced heal
Publikováno v:
American family physician. 91(10)